SAN JOSE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral ...
SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral ...
I'm initiating coverage on Rani Therapeutics Holdings, Inc. (RANI) and believe that I should set it at a Buy rating. The reason why I believe that I should do this is because of three major pipeline ...
SAN JOSE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral ...
Rani Therapeutics Holdings, Inc. announced that it will present preclinical data on its RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) in San Francisco from July 12-15, 2025.
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus ...
- Data adds to growing body of evidence of the RaniPill ® platform’s potential to enable oral delivery of multiple obesity treatments - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for ...
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics ...
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics” or "Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results